RhoA/Rho-Kinase as a therapeutic target for the male urogenital tract

Journal of Sexual Medicine

Volumn 8, Issue 3, 2011, Pages 675-687

  Gur, Serap ^a   Kadowitz, Philip J ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Kidney; Prostate; Rho kinase; Sexual Function; Urethra; Urinary Bladder

Indexed keywords

CALCIUM ION; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

AGING; ARTICLE; BLADDER CANCER; CASTRATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; HYPOXIA; KIDNEY CARCINOMA; KIDNEY FAILURE; MEDLINE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN TARGETING; RENOVASCULAR DISEASE; URETER; URETHRA; UROGENITAL SYSTEM; UROGENITAL TRACT DISEASE; VAS DEFERENS;

EID: 79951989467     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02084.x     Document Type: Review

References (104)

1. Shabir S, Borisova L, Wray S, Burdyga T. Rho-kinase inhibition and electromechanical coupling in rat and guinea-pig ureter smooth muscle: Ca2+-dependent and -independent mechanisms. J Physiol 2004;560:839-55.
2. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-58.
3. Brown ME, Bridgman PC. Myosin function in nervous and sensory systems. J Neurobiol 2004;58:118-30.
4. Ikebe M, Hartshorne DJ, Elzinga M. Identification, phosphorylation, and dephosphorylation of a second site for myosin light chain kinase on the 20, 000-dalton light chain of smooth muscle myosin. J Biol Chem 1986;261:36-9.
5. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189-93.
6. Nakashima S, Tabuchi K, Shimokawa S, Fukuyama K, Mineta T, Abe M. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 1998;38:805-10. discussion 10-1.
7. Shirotani M, Yui Y, Hattori R, Kawai C. A new type of vasodilator, HA1077, an isoquinoline derivative, inhibits proliferation of bovine vascular smooth muscle cells in culture. J Pharmacol Exp Ther 1991;259:738-44.
8. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: Sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 2008;48:241-7. discussion 7-8.
9. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007;28:296-302.
10. Hashitani H, Yanai Y, Suzuki H. Role of interstitial cells and gap junctions in the transmission of spontaneous Ca2+ signals in detrusor smooth muscles of the guinea-pig urinary bladder. J Physiol 2004;559:567-81.
11. Roosen A, Wu C, Sui GP, Fry CH. Synergistic effects in neuromuscular activation and calcium-sensitization in the bladder trigone. BJU Int 2008;101:610-4.
12. Fleichman M, Schneider T, Fetscher C, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. J Pharmacol Exp Ther 2004;308:54-8.
13. Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 2003;138:757-66.
14. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004;309:1148-53.
15. Hashitani H, Bramich NJ, Hirst GD. Mechanisms of excitatory neuromuscular transmission in the guinea-pig urinary bladder. J Physiol 2000;524:Pt 2:565-79.
16. Heppner TJ, Bonev AD, Nelson MT. Elementary purinergic Ca2+ transients evoked by nerve stimulation in rat urinary bladder smooth muscle. J Physiol 2005;564:201-12.
17. Rajasekaran M, Mehta N, Baquir A, Kuntz S. Rho-kinase inhibition suppresses potassium chloride-induced bladder hyperactivity in a rat model. Urology 2007;69:791-4.
18. Quinn T, Collins C, Baird AW. Mechanisms of neurokinin A- and substance P-induced contractions in rat detrusor smooth muscle in vitro. BJU Int 2004;94:651-7.
19. Turner WH, Brading AF. Smooth muscle of the bladder in the normal and the diseased state: Pathophysiology, diagnosis and treatment. Pharmacol Ther 1997;75:77-110.
20. Yoshimura N, Chancellor MB, Andersson KE, Christ GJ. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int 2005;95:733-8.
21. Nobe K, Yamazaki T, Tsumita N, Hashimoto T, Honda K. Glucose-dependent enhancement of diabetic bladder contraction is associated with a rho kinase-regulated protein kinase C pathway. J Pharmacol Exp Ther 2009;328:940-50.
22. Ismael HN, Mustafa S, Thulesius O. Effect of diabetes on cooling-induced detrusor muscle contraction: Mediation via Rho-kinase activation. Urology 2010;75:891-5.
23. Rajasekaran M, Wilkes N, Kuntz S, Albo EM. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats. Neurourol Urodyn 2005;24:295-300.
24. Nobe K, Yamazaki T, Kumai T, Okazaki M, Iwai S, Hashimoto T, Kobayashi S, Oguchi K, Honda K. Alterations of glucose-dependent and -independent bladder smooth muscle contraction in spontaneously hypertensive and hyperlipidemic rat. J Pharmacol Exp Ther 2008;324:631-42.
25. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009;6:1594-608.
26. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003;170:2517-22.
27. Takahashi N, Shiomi H, Kushida N, Liu F, Ishibashi K, Yanagida T, Shishido K, Aikawa K, Yamaguchi O. Obstruction alters muscarinic receptor-coupled RhoA/Rho-kinase pathway in the urinary bladder of the rat. Neurourol Urodyn 2009;28:257-62.
28. Takahashi R, Nishimura J, Seki N, Yunoki T, Tomoda T, Kanaide H, Naito S. RhoA/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate. Neurourol Urodyn 2007;26:547-51.
29. Bing W, Chang S, Hypolite JA, DiSanto ME, Zderic SA, Rolf L, Wein AJ, Chacko S. Obstruction-induced changes in urinary bladder smooth muscle contractility: A role for Rho kinase. Am J Physiol Renal Physiol 2003;285:F990-7.
30. Juan YS, Li S, Levin RM, Kogan BA, Schuler C, Leggett RE, Huang CH, Mannikarottu A. The effect of ischemia/reperfusion on rabbit bladder-role of Rho-kinase and smooth muscle regulatory proteins. Urology 2009;73:1126-30.
31. Michael L, Sweeney DE, Davies JA. A role for microfilament-based contraction in branching morphogenesis of the ureteric bud. Kidney Int 2005;68:2010-8.
32. Hong SK, Kwak C, Chang Jeong B, Kim BS, Kim HH. Involvement of Rho-kinase in the contractile mechanism of human ureteral smooth muscle. Neurourol Urodyn 2005;24:136-41.
33. Turna B, Cinar MG, Canda AE, Orhan EC, Tiftik NR, Nazli O, Buyukafsar K. Role of Rho-kinase in contractions of ureters from rabbits with unilateral ureteric obstruction. BJU Int 2007;100:1166-71.
34. Levent A, Buyukafsar K. Expression of Rho-kinase (ROCK-1 and ROCK-2) and its substantial role in the contractile activity of the sheep ureter. Br J Pharmacol 2004;143:431-7.
35. Canda AE, Cinar MG, Turna B, Sahin MO. Pharmacologic targets on the female urethra. Urol Int 2008;80:341-54.
36. Teixeira CE, Jin L, Priviero FB, Ying Z, Webb RC. Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract. Biochem Pharmacol 2007;74:647-58.
37. Holmquist F, Persson K, Bodker A, Anderson KE. Some pre- and postjunctional effects of castration in rabbit isolated corpus cavernosum and urethra. J Urol 1994;152:1011-6.
38. Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male 2008;11:51-5.
39. Szaszi K, Sirokmany G, Di Ciano-Oliveira C, Rotstein OD, Kapus A. Depolarization induces Rho-Rho kinase-mediated myosin light chain phosphorylation in kidney tubular cells. Am J Physiol Cell Physiol 2005;289:C673-85.
40. Meyer TN, Schwesinger C, Sampogna RV, Vaughn DA, Stuart RO, Steer DL, Bush KT, Nigam SK. Rho kinase acts at separate steps in ureteric bud and metanephric mesenchyme morphogenesis during kidney development. Differentiation 2006;74:638-47.
41. Hayashi K, Wakino S, Kanda T, Homma K, Sugano N, Saruta T. Molecular mechanisms and therapeutic strategies of chronic renal injury: Role of rho-kinase in the development of renal injury. J Pharmacol Sci 2006;100:29-33.
42. Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 2009;296:R1001-18.
43. Roos MH, van Rodijnen WF, van Lambalgen AA, ter Wee PM, Tangelder GJ. Renal microvascular constriction to membrane depolarization and other stimuli: Pivotal role for rho-kinase. Pflugers Arch 2006;452:471-7.
44. Ruperez M, Sanchez-Lopez E, Blanco-Colio LM, Esteban V, Rodriguez-Vita J, Plaza JJ, Egido J, Ruiz-Ortega M. The Rho-kinase pathway regulates angiotensin II-induced renal damage. Kidney Int Suppl 2005;99:S39-45.
45. Inscho EW, Cook AK, Webb RC, Jin LM. Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter. Am J Physiol Renal Physiol 2009;296:F590-7.
46. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, Rodrigues Diez R, Selgas R, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008;25:2447-61.
47. Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 2008;19:2086-97.
48. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002;61:1684-95.
49. Krepinsky JC, Ingram AJ, Tang D, Wu D, Liu L, Scholey JW. Nitric oxide inhibits stretch-induced MAPK activation in mesangial cells through RhoA inactivation. J Am Soc Nephrol 2003;14:2790-800.
50. Bussemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J. Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis 2009;207:567-72.
51. Wakino S, Kanda T, Hayashi K. Rho/Rho kinase as a potential target for the treatment of renal disease. Drug News Perspect 2005;18:639-43.
52. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, Ono H, Matsuoka H. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 2007;25:1053-63.
53. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T, Shimokawa H. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 2002;455:169-74.
54. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. J Hypertens 2008;26:1837-48.
55. Winaver J, Ovcharenko E, Rubinstein I, Gurbanov K, Pollesello P, Bishara B, Hoffman A, Abassi Z. Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 2006;290:H2007-14.
56. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, Abe Y, Nishiyama A. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006;17:2193-201.
57. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008;57:714-23.
58. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, Kurata H, Tajima N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007;568:242-7.
59. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007;192:595-603.
60. Morelli A, Chavalmane AK, Filippi S, Fibbi B, Silvestrini E, Sarchielli E, Zhang XH, Vignozzi L, Vannelli GB, Forti G, Maggi M. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med 2009;6:91-106.
61. Fibbi B, Morelli A, Marini M, Zhang XH, Mancina R, Vignozzi L, Filippi S, Chavalmane A, Silvestrini E, Colli E, Adorini L, Vannelli GB, Maggi M. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl 2008;29:70-84.
62. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A 2002;99:8301-5.
63. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, McKenzie R, Krepinsky JC. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008;57:1683-92.
64. Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T, Tanaka M, Tatsumiya K, Furuya N, Masuda A, Yamanishi T, Yoshida K. Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 2008;29:155-61.
65. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652-9.
66. Muller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, Buettner R, Schule R. The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 2002;21:736-48.
67. Yao H, Dashner EJ, van Golen CM, van Golen KL. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 2006;25:2285-96.
68. Papadopoulou N, Charalampopoulos I, Alevizopoulos K, Gravanis A, Stournaras C. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells. Exp Cell Res 2008;314:3162-74.
69. Mills TM, Chitaley K, Lewis RW. Vasoconstrictors in erectile physiology. Int J Impot Res 2001;13(suppl 5):S29-34.
70. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001;7:119-22.
71. Villalba N, Stankevicius E, Simonsen U, Prieto D. Rho kinase is involved in Ca2+ entry of rat penile small arteries. Am J Physiol Heart Circ Physiol 2008;294:H1923-32.
72. Villalba N, Stankevicius E, Garcia-Sacristan A, Simonsen U, Prieto D. Contribution of both Ca2+ entry and Ca2+ sensitization to the alpha1-adrenergic vasoconstriction of rat penile small arteries. Am J Physiol Heart Circ Physiol 2007;292:H1157-69.
73. Wingard CJ, Husain S, Williams J, James S. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2003;285:R1145-52.
74. Chitaley K, Bivalacqua TJ, Champion HC, Usta MF, Hellstrom WJ, Mills TM, Webb RC. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun 2002;298:427-32.
75. Teixeira CE, Ying Z, Webb RC. Proerectile effects of the Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis. J Pharmacol Exp Ther 2005;315:155-62.
76. Rees RW, Ziessen T, Ralph DJ, Kell P, Moncada S, Cellek S. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002;14:1-7.
77. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 2007;51:1732-40.
78. Mills TM, Chitaley K, Lewis RW, Webb RC. Nitric oxide inhibits RhoA/Rho-kinase signaling to cause penile erection. Eur J Pharmacol 2002;439:173-4.
79. Wang H, Eto M, Steers WD, Somlyo AP, Somlyo AV. RhoA-mediated Ca2+ sensitization in erectile function. J Biol Chem 2002;277:30614-21.
80. Mills TM, Chitaley K, Wingard CJ, Lewis RW, Webb RC. Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol 2001;91:1269-73.
81. Gur S, Kadowitz PJ, Trost L, Hellstrom WJ. Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum. J Urol 2007;178:1543-8.
82. Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 2001;133:455-8.
83. Chitaley K, Webb RC, Dorrance AM, Mills TM. Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats. Int J Impot Res 2001;13(suppl 5):S16-20.
84. Carneiro FS, Nunes KP, Giachini FR, Lima VV, Carneiro ZN, Nogueira EF, Leite R, Ergul A, Rainey WE, Clinton Webb R, Tostes RC. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension. J Sex Med 2008;5:2793-807.
85. Wingard CJ, Johnson JA, Holmes A, Prikosh A. Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 2003;284:R1572-9.
86. Dai Y, Chitaley K, Webb RC, Lewis RW, Mills TM. Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impot Res 2004;16:294-8.
87. Chang S, Hypolite JA, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003;15:53-62.
88. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, Kadowitz PJ. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 2004;101:9121-6.
89. Buyukafsar K, Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 2003;472:235-8.
90. Wingard CJ, Moukdar F, Prasad RY, Cathey BL, Wilkinson L. Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signaling. J Sex Med 2009;6(suppl 3):269-78.
91. Gao BH, Zhao ST, Meng FW, Shi BK, Liu YQ, Xu ZS. Y-27632 improves the erectile dysfunction with ageing in SD rats through adjusting the imbalance between nNo and the Rho-kinase pathways. Andrologia 2007;39:146-50.
92. Gur S, Kadowitz PJ, Hellstrom WJ. A critical appraisal of erectile function in animal models of diabetes mellitus. Int J Androl 2009;32:93-114.
93. Li WJ, Park K, Paick JS, Kim SW. Chronic Treatment with an Oral Rho-Kinase Inhibitor Restores Erectile Function by Suppressing Corporal Apoptosis in Diabetic Rats. J Sex Med 2010;Mar 2 [Epub ahead of print] doi: 10.1111/j.1743-6109.2010.01724.x.
94. Filippi S, Marini M, Vannelli GB, Crescioli C, Granchi S, Vignozzi L, Luconi M, Ferruzzi P, Morelli A, Forti G, Ledda F, Maggi M. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. Mol Hum Reprod 2003;9:765-74.
95. Gur S, Kadowitz PJ, Hellstrom WJ. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction Implications for sexual dysfunction. Drugs 2008;68:209-29.
96. McVary K. Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. BJU Int 2006;97(suppl 2):23-8. discussion 44-5.
97. Lin WY, Mannikarottu A, Chichester P, Neuman P, Johnson A, Perez-Martinez FC, Levin RM. The effect of chronic partial bladder outlet obstruction on corpus cavernosum smooth muscle and Rho-kinase in rabbits. Neurourol Urodyn 2008;27:826-31.
98. Demir O, Murat N, Aslan G, Gidener S, Esen AA. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J Urol 2006;175:2345-9.
99. Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Burnett AL. Elevated RhoA/Rho-kinase activity in the aged rat penis: Mechanism for age-associated erectile dysfunction. FASEB J 2006;20:536-8.
100. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Conley EC, Buell G, Pritchard CA, Evans RJ. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 2000;403:86-9.
101. Buyukafsar K, Levent A, Ark M. Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens. Br J Pharmacol 2003;140:743-9.
102. Wier WG, Zang WJ, Lamont C, Raina H. Sympathetic neurogenic Ca2+ signalling in rat arteries: ATP, noradrenaline and neuropeptide Y. Exp Physiol 2009;94:31-7.
103. Liu CM, Lo YC, Wu BN, Wu WJ, Chou YH, Huang CH, An LM, Chen IJ. cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy. Prostate 2007;67:1397-410.
104. Malmqvist U, Hedlund P, Sward K, Andersson KE. Female pig urethral tone is dependent on Rho guanosine triphosphatases and Rho-associated kinase. J Urol 2004;171:1955-8.